Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Munich - Delayed Quote • EUR CureVac NV (5CV.MU) Follow Add holdings 2.8260 +0.0420 +(1.51%) At close: April 23 at 8:04:10 AM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 5CV.MU 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 5CV.MU View More All News Press Releases SEC Filings Vaccine Stocks Rise on Growing Threat of Bird Flu Infections CureVac Among 3 Promising Penny Stocks To Watch Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience Q4 2024 CureVac NV Earnings Call CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 FDA clears CureVac’s IND application for Phase I lung cancer trial CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer Is CureVac (CVAC) the Best German Stock to Buy According to Hedge Funds? Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz